You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table. Parameters used in relative risk calculations for ehrlichiosis and Lyme disease, by vector, Monmouth County, New Jersey, USA*  

Parameter Ixodes scapularis Amblyomma americanum
Relative abundance of each species CIS  = 38.32 CAA  = 61.68
Adults Nymphs Adults Nymphs
Relative abundance of each life stage CIS. D = 19.96 CIS. N = 80.04 CAA. D = 35.34 CAA. N  = 64.66
Infection rates per life stage IIS. D = 39.87 IIS. N = 23.3 IAA. D = 11.7 IAA. N = 9.04
Infection rates, weighted IIS = 26.60 IAA = 9.98

Table. Parameters used in relative risk calculations for ehrlichiosis and Lyme disease, by vector, Monmouth County, New Jersey, USA*

*Values are in percentages. Relative abundances (denoted by CX ) are derived from specimens submitted to the Monmouth County Mosquito Control Division’s tick identification and testing service during peak Lyme disease transmission season (May–August) and during a 10-year period (2006–2015). Infection rates of I. scapularis ticks with Borrelia burgdorferi (IIS ) also from passive surveillance program. Infection rates of A. americanum ticks (IAA ) encompass both Ehrlichia chaffeensis and E. ewingii (accounting for co-infection).

CME

Relative Risk for Ehrlichiosis and Lyme Disease in an Area Where Vectors for Both Are Sympatric, New Jersey, USA

  • Authors: Andrea Egizi, PhD, Nina H. Fefferman, PhD, Robert A. Jordan, PhD
  • CME Released: 5/11/2017
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 5/11/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, infectious disease specialists, and other physicians who care for patients at risk for tick-borne illnesses.

The goal of this activity is to compare the prevalence of ehrlichiosis vs Lyme disease based on analytical models and case reports to public health agencies.

Upon completion of this activity, participants will be able to:

  1. Analyze the clinical presentation of ehrlichiosis
  2. Compare the vectors of ehrlichiosis vs Lyme disease
  3. Distinguish the ratio of ehrlichiosis to Lyme disease using a mathematical model
  4. Compare predicted rates of ehrlichiosis with actual reported rates of illness


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Andrea Egizi, PhD

    Monmouth County Mosquito Control Division, Tinton Falls, New Jersey, USA; Rutgers University, New Brunswick, New Jersey, USA

    Disclosures

    Disclosure: Andrea Egizi, PhD, has disclosed no relevant financial relationships.

  • Nina H. Fefferman, PhD

    University of Tennessee, Knoxville, Tennessee, USA; Rutgers University, New Brunswick, New Jersey, USA

    Disclosures

    Disclosure: Nina H. Fefferman, PhD, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: VIVUS, Inc.

  • Robert A. Jordan, PhD

    Monmouth County Mosquito Control Division, Tinton Falls, New Jersey, USA; Rutgers University, New Brunswick, New Jersey, USA

    Disclosures

    Disclosure: Robert A. Jordan, PhD, has disclosed no relevant financial relationships.

Editor

  • Jude Rutledge, BA

    Copyeditor, Emerging Infectious Diseases

    Disclosures

    Disclosure: Jude Rutledge, BA, has disclosed no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor, UC Irvine Department of Family Medicine; Associate Dean for Diversity and Inclusion, UC Irvine School of Medicine, Irvine, California

    Disclosures

    Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: McNeil Consumer Healthcare
    Served as a speaker or a member of a speakers bureau for: Shire Pharmaceuticals

CME Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements




In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Relative Risk for Ehrlichiosis and Lyme Disease in an Area Where Vectors for Both Are Sympatric, New Jersey, USA: Methods

processing....

Methods

Site Description

Monmouth County (40°44′N, 74°17′W) is located in eastern-central New Jersey, a US state on the mid-Atlantic coast. The county is 468.8 mi2 in size and had a population of 630,380 (1,344.7 persons/mi2) as of the 2010 census (http://www.census.gov/quickfacts/table/PST045215/34025). The geomorphologic break separating the Inner and Outer Coastal Plain physiographic provinces in New Jersey runs horizontally across the center of the county, and the resulting soil differences are reflected in vegetative differences between these 2 regions.[20] The Outer Coastal Plain region is characterized by sandier soils that are often dry and acidic, with pine forests and cedar swamps. Previously, the distribution of A. americanum ticks in Monmouth County was restricted to this southern part of the county,[21] whereas I. scapularis ticks were found throughout. However, recently specimens of A. americanum ticks have been captured in the far north and west of the county.

The county reports several hundred cases of Lyme disease annually, with a 10-year average (during 2005–2014) of 361 cases/year. By contrast, during that same period, there were on average 5.5 cases/year of E. chaffeensis infection and no cases of infection attributed to E. ewingii.[22]

Risk Model

The relative risk for infection with a tickborne pathogen depends on multiple factors, including risk for exposure to a competent vector, risk for exposure to the pathogen from exposure to the vector, and risk for transmission from exposure to a pathogen-infected vector. To characterize the risk for human exposure to ticks, we define the parameter Cx as the relative proportion of each species (x) of tick submitted to the Monmouth County Mosquito Control Division’s tick identification and testing service. This passive surveillance program, initiated in 2006, allows county residents to submit ticks they have encountered (e.g., found on their skin or clothing) for species identification. This program averages 658.9 submissions/year, although this number has increased markedly in recent years (R.A. Jordan, unpub. data). For Cx , we used the 10-year average of relative submissions data (2006–2015) during peak Lyme disease transmission season in New Jersey (May–August) ( Table ). Although in Monmouth A. americanum ticks are often 3 times as abundant as I. scapularis ticks in field collections,[9] using the passive surveillance data in our model (where A. americanum ticks are only encountered 1.5 times as often; Table ) provides a more direct measure of human exposure to ticks as well as a more conservative risk estimate.

To characterize risk for exposure to the disease from the vector, we define Ix as the prevalence of the pathogen in ticks (i.e., percentage infected), weighted by life stage. Both I. scapularis and A. americanum ticks have a 3-host life cycle, meaning that adults have had more opportunities to feed on an infected host than nymphs and consequently infection rates differ between life stages. Because transovarial transmission of either B. burgdorferi or E. chaffeensis does not occur,[23,24] host-seeking larvae are not infected and therefore were not included in the calculations. Relative abundance of nymphs and adults of each species submitted to our passive tick surveillance program during May–August were reported (CX,N and CX,D ) and used to weight the infection prevalence of each ( Table ). Infection rates of I. scapularis ticks with B. burgdorferi for both life stages (IIS,D and IIS,N ) also were obtained from our passive surveillance program, whereby residents submitting an I. scapularis tick can elect to have it tested for B. burgdorferi through nested PCR assay (following established protocols [8]). Our records show that during a 10-year period of our program, 90.5% of residents submitting I. scapularis ticks during May–August have chosen to have them tested (R.A. Jordan, unpub. data), including 153 adults and 1,146 nymphs. However, the program does not test A. americanum ticks, so infection rates for this species were obtained from other sources. Rates of adult tick infection with E. chaffeensis and E. ewingii (IAA,D ) in Monmouth County were derived from Schulze et al.[21] and summed, yielding a total value (accounting for co-infected ticks) of 11.7% infection with human Ehrlichia pathogens (N = 291). Nymphal infection rates with both ehrlichia species were obtained from an unpublished dataset consisting of field-collected nymphs from 4 sites in eastern and western Monmouth County in 2014 (R.A. Jordan unpub. data). Nymphal specimens were disrupted by using a TissueLyser and DNA isolated with QIAgen DNeasy 96 well-plate blood and tissue kits (QIAGEN, Valencia, CA, USA). Specimens were tested for pathogens by using real-time PCR protocols for E. chaffeensis[25] and E. ewingii.[26] Both probes were modified slightly (shortened) to allow the use of an MGB quencher as follows (5′–3′): VIC-CGGACAATTGCTTATAACC-MGBNFQ for E. chaffeensis and 6FAM-AACAATTCCTAAATAGTCTCTGAC-MGBNFQ for E. ewingii. Sequence detection primers and reaction conditions were as described previously.[26] A subset of samples was compared with conventional PCR methods established by this laboratory for detection of these pathogens,[21] and the 2 methods were found to be in agreement. The resulting infection prevalence of Ehrlichia pathogens in A. americanum nymphs (IAA,N ) (encompassing E. chaffeensis and E. ewingii, accounting for coinfection) was 9.04% (N = 752). Overall infection prevalence (Ix ) in each species of tick, weighted by life stage, was calculated by multiplying the relative abundance of each life stage times its infection rate and summing across life stages ( Table ).

To characterize transmission risk, we defined TX as the likelihood of successful pathogen transmission from an infected tick to a human. The general concept of vector competence includes both this direction of transmission from vector to host as well as the probability of the vector becoming infected from feeding on infected hosts, which in our calculations is already reflected in tick infection rates (Ix ). Data on transmission efficiency to animals for both species is scarce because most studies feed multiple infected ticks on 1 host (so the risk imposed by a single feeding tick is unknown) and, because of the difficulty in working with large vertebrates in a laboratory setting, have very small sample sizes.[27–30] Further, whether probabilities of transmission obtained from animal studies are applicable to humans is unknown. Therefore, although we are including the parameter TX in the equation so that it can be applied when such data become better known, for purposes of these analyses we are setting it equal to 1 for both diseases, yielding no functional impact on the model.

Calculations

Based on our definitions, we calculate the relative risk for ehrlichiosis compared to Lyme disease as risk = (CAA × IAA × TAA )/(CIS × IIS × TIS ). To then translate this value into expected cases of observed human infection, we move from risk to reported case numbers by using the reported number of cases of Lyme disease in Monmouth County as a benchmark. In other words, if there were X Lyme disease cases, then the expected number of ehrlichiosis cases would be X multiplied by the relative risk estimate calculated as described.